- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03506009
Argatroban Plus r-tPA for Posterior Circulation Infarction(AR-PCI)
Argatroban Plus R-tPA for Acute Posterior Circulation Infarction (AR-PCI): a Prospective, Random, Blinded Assessment of Outcome and Open Label Multi-center Study
Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of morbidity, mortality and disability. A large number of studies have confirmed that the thrombolytic therapy can effectively open blood vessels and improve the functional prognosis of acute ischemic stroke. Therefore, all guidelines recommend giving thrombolysis treatment to acute ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients receiving thrombolysis will have good prognosis, while a large number of patients will still be disabled and even dead. How to improve the neurofunction prognosis of thrombolytic patients has been a hot topic in the world.
Recent studies have found that the combined application of argatroban and rt-PA in the treatment of acute anterior circulation infarction might improve the clinical prognosis and not significantly increase bleeding. Some studies have reported that the combined application of argatroban and rt-PA could improve the blood vessel opening rate, and prevent re-occlusion after opening.
Based on the discussion, the present study is designed to explore the efficacy and safety of argatroban plus rt-PA in the treatment of acute posterior circulation infarction.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Liaoning
-
Shenyang, Liaoning, China, 10016
- General Hospital of Shenyang Military Region
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-80 years old;
- Diagnosis of posterior circulation ischemic stroke;
- Time from onset to treatment ≤6 hours;
- NIHSS: 4-25;
- Signed informed consent by patient self or legally authorized representatives.
Exclusion Criteria:
- mRS≥2;
- History of stroke within 3 months;
- History of intracranial hemorrhage;
- Suspected subarachnoid hemorrhage;
- Intracranial tumour, vascular malformation or arterial aneurysm;
- Major surgery within 1 month;
- Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;
- Platelet count < 105/mm3;
- Heparin therapy or oral anticoagulation therapy within 48 hours;
- Abnormal APTT;
- Thrombin or Xa factor inhibitor;
- Severe disease with a life expectancy of less than 3 months;
- Blood glucose < 50 mg/dL (2.7mmol/L);
- Patients who have received any other investigational drug or device within 3 months;
- Pregnancy;
- Researchers consider patients inappropriate to participate in the registry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Argatroban combined with rt-PA
|
Argatroban as a 100-ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%).
|
Active Comparator: rt-PA
|
Intravenous throbolysis with 0.9mg/kg rtPA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of mRS (0-1)
Time Frame: 90±7 days
|
90±7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of mRS (0-2)
Time Frame: 90±7 days
|
90±7 days
|
|
Early neurological deterioration
Time Frame: 48 hours
|
4 or more increase in NIHSS
|
48 hours
|
the occurence of stroke
Time Frame: 90±7 days
|
90±7 days
|
|
symptomatic intracranial hemorrhage
Time Frame: 36 hours
|
36 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Infarction
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Protease Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Tissue Plasminogen Activator
- Argatroban
Other Study ID Numbers
- k(2017)29
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Argatroban, Rt-PA
-
Rajavithi HospitalUnknownTo Study Immunostatus of HIV-cancer Patients Who Recived RT Befor RT and Last Week of RT | To Study HIV Viral Load of HIV-cancer Patients Who Recived RT Befor RT and Last Week of RTThailand
-
Poitiers University HospitalUnknownThe Gold Standard for Current SARS CoV2 Detection is RT-PCRFrance
-
Rambam Health Care CampusCompletedPharmacological Action (PA)Israel
-
Centre Hospitalier Universitaire, AmiensCompletedSars-CoV2 | RT-PCR | Saliva Collection | Nasopharyngeal SampleFrance
-
Hospital de Clinicas José de San MartínClaudio Yaryour; Fermepin Marcelo; Luis Sarotto; Federico Rodriguez Cairoli; Angela... and other collaboratorsUnknownVirus Diseases | SARS-CoV 2 | COVID | Health Personnel Attitude | rt PCR | Personal Protective Equipment PPE
-
M.A. Med Alliance S.A.CompletedPatients With Peripheral Artery Disease in the SFA or PAGermany
-
National Taiwan University HospitalUnknownPropionic Acidemia (PA) , Methylmalonic Acidemia (MMA)Taiwan
-
University of AarhusOdense University Hospital; Copenhagen University Hospital at HerlevCompletedAdverse Effects for Adaptive RT of Bladder CancerDenmark
-
Huazhong University of Science and TechnologyCompletedVenous Thromboembolism | Gynecologic Neoplasms | Low Molecular Weight Heparin | ArgatrobanChina
-
AHS Cancer Control AlbertaCross Cancer InstituteWithdrawnLocally Advanced Cervical Cancer | Integrated MRI Based RT as Standard of Care
Clinical Trials on Argatroban combined with rt-PA
-
University of LisbonAssociacao Protectora dos Diabeticos de PortugalCompleted
-
Andrew D. Barreto, MDThe University of Texas Health Science Center, HoustonTerminatedIschemic StrokeUnited States
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Wuhan General Hospital of Guangzhou Military CommandUnknown
-
General Hospital of Shenyang Military RegionCompleted
-
Boehringer IngelheimCompleted
-
Rush University Medical CenterUniversity of Illinois at Chicago; Michigan State UniversityActive, not recruitingPhysical ActivityUnited States
-
Tasly Biopharmaceuticals Co., Ltd.RecruitingAcute Ischemic StrokeChina
-
University College, LondonRecruiting